Blood molybdenum level as a marker of cancer risk among BRCA1 carriers-Reference-Cited by-同舟云学术

Blood molybdenum level as a marker of cancer risk among BRCA1 carriers

Published:2024-06-04 Issue: Volume: Page:
ISSN:
Container-title:
language:
Short-container-title:

Author:

Matuszczak Milena¹,Kiljańczyk Adam¹,Marciniak Wojciech²,Derkacz Róża²,Stempa Klaudia³,Baszuk Piotr¹,Bryśkiewicz Marta¹,Cybulski Cezary¹,Dębniak Tadeusz¹,Gronwald Jacek¹,Huzarski Tomasz¹,Lener Marcin¹,Jakubowska Anna¹,Pietrzak Sandra¹,Szwiec Marek⁴,Stawicka-Niełacna Małgorzata³,Godlewski Dariusz⁵,Prusaczyk Artur⁶,Jasiewicz Andrzej⁷,Kluz Tomasz⁸,Tomiczek-Szwiec Joanna⁹,Kobierzycka Ewa Kilar-¹⁰,Siołek Monika¹¹,Wiśniowski Rafał¹²,Posmyk Renata¹³,Jarkiewicz-Tretyn Joanna¹⁴,Sun Ping¹⁵,Cheriyan Angela¹⁵,Scott Rodney¹⁶,Narod Steven¹⁵,Lubinski Jan²

Affiliation:

1. Department of Genetics and Pathology, International Hereditary Cancer Center, Pomeranian Medical University

2. Read-Gene, Dobra (Szczecińska)

3. Department of Clinical Genetics and Pathology, University of Zielona Góra

4. Department of Surgery and Oncology, University of Zielona Góra

5. OPEN

6. Medical and Diagnostic Center

7. Genetic Counseling Center, Subcarpatian Oncological Hospital

8. Medical College of Rzeszow University

9. University of Opole

10. Department of Oncology, District Specialist Hospital,

11. Holycross Cancer Center

12. Regional Oncology Hospital

13. Department of Clinical Genetics, Medical University in Bialystok,

14. Non-Public Health Care Centre, Cancer Genetics Laboratory,

15. Women’s College Research Institute, University of Toronto

16. University of Newcastle

Abstract

Purpose:A large proportion of ovarian and breast cancer cases are due to genetic predisposition. Women with a mutation in the BRCA1 gene have an up to an 80% chance of developing breast cancer and 40% chance of developing ovarian cancer. No studies to date assess exposure to molybdenum and cancer risk. The purpose of our study was to see if exposure to molybdenum modifies cancer risk in BRCA1 mutation carriers. Material and Methods: The study included 989 initially unaffected women with a BRCA1 mutation. The mean follow-up time was 6.8 years. During this time, 172 cancers occurred including 121 breast, 29 ovarian and 22 cancers at other sites. The cohort was stratified into three categories (tertiles) based on the blood level of molybdenum (<0.54 µg/L, 0.54-0.70 µg/L and >0.70 µg/L) with the lowest tertile forming the reference group. Cox proportional hazards models were used to model the association between blood molybdenum levels and cancer incidence. Results:A high blood molybdenum level (>0.70 µg/L) was associated with a significantly increased risk of developing ovarian cancer (HR = 5.55; 95%CI: 1.59-19.4; p = 0.007) and of any cancer (HR = 1.74; 95%CI: 1.17-2.61; p = 0.007) but not of breast cancer (HR = 1.46, CI= 0.91-2.33; p = 0.12). Conclusion:It is possible that lowering molybdenum levels may reduce the risk of cancer among women with a pathogenic germline variant in BRCA1.

Publisher

Springer Science and Business Media LLC

Reference11 articles.

1. Based on a Biological Monitoring Study of Sanitation Workers;Li Z;Environ Sci Pollut Res,2022

2. Assessment of Molybdenum Toxicity in Humans;Vyskočil A;J Appl Toxicol,1999

3. Occupational Risk Factors of Lung Cancer: A Hospital Based Case-Control Study;Droste JH;Occup Environ Med,1999

4. The Risk of Breast Cancer in Women with a BRCA1 Mutation from North America and Poland;Lubinski J;Int J Cancer,2012

5. Institute of Medicine (US) (2001) Panel on Micronutrients. Dietary Reference Intakes for Vitamin A, Vitamin K, Arsenic, Boron, Chromium, Copper, Iodine, Iron, Manganese, Molybdenum, Nickel, Silicon, Vanadium, and Zinc. National Academies, Washington, D.C.. https://doi.org/10.17226/10026.